Bloos, Frank http://orcid.org/0000-0002-0767-7941
Held, Jürgen http://orcid.org/0000-0003-1130-9727
Kluge, Stefan http://orcid.org/0000-0001-8391-3988
Simon, Philipp http://orcid.org/0000-0003-2696-3254
Kogelmann, Klaus http://orcid.org/0000-0003-4308-9319
de Heer, Geraldine http://orcid.org/0000-0003-1950-8683
Kuhn, Sven-Olaf http://orcid.org/0000-0003-2961-4578
Jarczak, Dominik http://orcid.org/0000-0003-0480-2089
Motsch, Johann
Hempel, Gunther http://orcid.org/0000-0002-9705-5184
Weiler, Norbert
Weyland, Andreas http://orcid.org/0000-0002-3468-6915
Drüner, Matthias http://orcid.org/0000-0001-9979-5904
Gründling, Matthias http://orcid.org/0000-0002-2498-1953
Meybohm, Patrick http://orcid.org/0000-0002-2666-8696
Richter, Daniel http://orcid.org/0000-0003-1786-5919
Jaschinski, Ulrich http://orcid.org/0000-0002-3318-0234
Moerer, Onnen http://orcid.org/0000-0002-4210-388X
Günther, Ulf
Schädler, Dirk http://orcid.org/0000-0002-5745-4797
Weiss, Raphael
Putensen, Christian
Castellanos, Ixchel http://orcid.org/0000-0001-7091-5423
Kurzai, Oliver http://orcid.org/0000-0002-7277-2646
Schlattmann, Peter http://orcid.org/0000-0001-7420-7707
Cornely, Oliver A. http://orcid.org/0000-0001-9599-3137
Bauer, Michael http://orcid.org/0000-0002-1521-3514
Thomas-Rüddel, Daniel http://orcid.org/0000-0001-9143-8566
Jaschinski, Ulrich
Putensen, Christian
Drüner, Matthias http://orcid.org/0000-0001-9979-5904
Castellanos, Ixchel http://orcid.org/0000-0001-7091-5423
Schmidt, Stefanie
Wehrfritz, Andreas
Kränzlein, Diana
Held, Jürgen http://orcid.org/0000-0003-1130-9727
Zacharowski, Kai
Mutlak, Haitham
Lindau, Simone
Wiedenbeck, Carolin
Mörer, Onnen
Kuhn, Sven-Olaf http://orcid.org/0000-0003-2961-4578
Gründling, Matthias http://orcid.org/0000-0002-2498-1953
Kluge, Stephan
de Heer, Geraldine
Jarczak, Dominik http://orcid.org/0000-0003-0480-2089
Motsch, Johann
Richter, Daniel http://orcid.org/0000-0003-1786-5919
Weigand, Markus A.
Bloos, Frank http://orcid.org/0000-0002-0767-7941
Bauer, Michael http://orcid.org/0000-0002-1521-3514
Thomas-Rüddel, Daniel http://orcid.org/0000-0001-9143-8566
Schlattmann, Peter http://orcid.org/0000-0001-7420-7707
Lehmann, Thomas
Weiler, Norbert
Schädler, Dirk http://orcid.org/0000-0002-5745-4797
Cornely, Oliver A. http://orcid.org/0000-0001-9599-3137
Simon, Philipp http://orcid.org/0000-0003-2696-3254
Hempel, Gunther http://orcid.org/0000-0002-9705-5184
Weiss, Raphael
Zarbock, Alexander
Günther, Ulf
Rohe, Georg
Weyland, Andreas http://orcid.org/0000-0002-3468-6915
Kurzai, Oliver http://orcid.org/0000-0002-7277-2646
Walter, Grit
Meybohm, Patrick http://orcid.org/0000-0002-2666-8696
Helmer, Philipp
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
(1 → 3)-β-d-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial
https://doi.org/10.1007/s00134-022-06733-x
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01EO1502)
Deutsche Forschungsgemeinschaft (390713860, PU219/2-3)
Universitätsklinikum Jena
Article History
Received: 20 February 2022
Accepted: 7 May 2022
First Online: 16 June 2022
Declarations
:
: FB received honoraria for an expert board meeting by Baxter. Prof. Cornely reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Jannsen, MedPace, Paratek, PSI, Shionogi; A pending patent currently reviewed at the German Patent and Trade Mark Office; Other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley. JH received grants and speaker honoraria from Pfizer, speaker honoraria from Gilead and consumables/test kits from Associates of Cape Cod. SK received research support from Cytosorbents and Daiichi Sankyo. He also received lecture fees from Astra, Bard, Baxter, Biotest, Cytosorbents, Daiichi Sankyo, Fresenius Medical Care, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Philips and Zoll. He received consultant fees from Fresenius, Gilead, MSD and Pfizer. KK received honoraria for lecturing from Cytosorbents, Fresenius and Sedana. CP received lecture fees from Astra, C.R.Bard, Baxter, Biotest, Cytosorbents, Daiichi Sankyo, Fresenius, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Philips and Zoll. He received consultant fees from Bayer, Fresenius, Gilead, MSD and Pfizer. He also received consultant fees from Messer, Pluristem, and Sedana and received lecture fees from Dräger Med. Inc. and Medronic. OM received honoraria for lectures during workshops on hemodynamic monitoring, supported by Pulsion (Maquet Critical Care) and for two lectures during industrial sessions at national congresses (HillRom, HepaWash); Unrestricted Research Grant from CSL Behring. DR has received support for attending meetings and/or travels from Gilead Sciences Inc., MSD, Pfizer. AW reported receiving honoraria for lecturing from Getinge and receiving personal fees from TEVA for consulting. No other disclosures were reported.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the Jena University Hospital and by the responsible Ethics Committees of the participating study centers.
: Written informed consent was obtained from all patients or their legal representatives, if available. In cases where consent could neither be obtained from the patient nor a legal representative in time before enrollment, the local ethics committee approved a delayed consent process. During this process the patient’s inability to provide consent was confirmed by an independent physician. As soon as the legal representative of the patient was available, written informed consent was immediately obtained, otherwise the patient was withdrawn from the study and all study procedures were ended.
: Not applicable.